Placeholder Banner

ICH: BIO Submits Comments on S11 Nonclinical Safety Testing in Support of Development of Pediatric Medicines

April 1, 2019

BIO submitted comments to the Food and Drug Administration (FDA) on the draft guidance, S11 Nonclinical Safety Testing in Support of Development of Pediatric Medicines.

BIO's comments address the use of datasets, in vitro nonclinical investigations, and the necessity of repeating juvenile toxicity studies on a prodrug of an approved drug when there may or may not be existing adult toxicity data for the prodrug.

Download Full Comments Below
BIO Comments On S11 Nonclinical Safety Testing In Support Of Development Of Pediatric Medicines FDA-2018-D-4524
Read full comment letter below
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…